Highline Wealth Partners
DGX icon

Highline Wealth Partners’s Quest Diagnostics DGX Stock Holding History

Highline Wealth Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.43K Buy
19
+4
+27% +$925 ﹤0.01% 944
2026
Q2 		$3.18K Buy
+15
New +$2.94K ﹤0.01% 1000
2025
Q3 		– Sell
-4
Closed -$719 – 1094
2025
Q2 		$719 Hold
4
– – ﹤0.01% 761
2025
Q1 		$677 Buy
+4
New +$657 ﹤0.01% 801
2023
Q4 		– Sell
-58
Closed -$7.07K – 418
2023
Q3 		$7.07K Buy
+58
New +$7.73K ﹤0.01% 209

Other funds holding DGX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Highline Wealth Partners's DGX Position: Q3 2026 in Review

Highline Wealth Partners increased its Quest Diagnostics (DGX) stake by 27% in Q3 2026, buying an estimated $925 and bringing the position to 19 shares worth $4.43K. The position accounts for ﹤0.01% of the portfolio, ranked #944.

Highline Wealth Partners first reported a position in DGX in Q3 2023 and has held it in 5 quarters since. The position peaked at $7.07K in Q3 2023. 978 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Highline Wealth Partners held 19 shares of Quest Diagnostics worth $4.43K as of Q3 2026.
  • Highline Wealth Partners bought 4 Quest Diagnostics shares in Q3 2026, an estimated $925.
  • Quest Diagnostics made up ﹤0.01% of Highline Wealth Partners's portfolio in Q3 2026, its #944 holding.
  • Highline Wealth Partners first reported a position in Quest Diagnostics in Q3 2023 and has held it in 5 quarters since.
  • Highline Wealth Partners's Quest Diagnostics position peaked at $7.07K in Q3 2023.
  • 978 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Highline Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.